🔍

Jeena Sikho Lifecare Limited (JSLL)

₹388.30 -0.10% last close, 16 Oct

📊 NSE: JSLL 🏢 Pharmaceuticals - Indian - Formulations 📢 Latest filing: 07 Oct 2026 📝 Analysis written: 14 Dec 2025

Latest quarterly results (Q1 FY27)

In its latest reported quarter, Q1 FY27, Jeena Sikho's revenue was ₹224 Cr (+28.8% year on year, +3.9% on the previous quarter), and net profit ₹65.9 Cr (+28.5% year on year); the operating margin was 41.0%.

Q1 FY27 (₹ Cr)	Value	YoY vs Q1 FY26	QoQ
Revenue	₹224	+28.8%	+3.9%
Operating profit	₹92.1	+16.9%	+18.0%
Net profit	₹65.9	+28.5%	+46.4%
EPS (₹)	5.30	+28.3%	+46.0%
Operating margin	41.0%	—	—

Full quarterly financials → Results calendar →

JSLL delivery percentage and bulk deals

NSE end-of-day data for Fri, 16 Oct 2026

On Fri, 16 Oct 2026, 45.72% of the JSLL shares traded on NSE were taken to delivery, against the stock's own 20-session average of 46.02%. That is close to its usual level. 1 bulk or block deal was reported in JSLL in the last 60 days: ₹29 Cr sold, none bought.

45.72%Delivery, 16 Oct

46.02%Own 20-session average

0.8×Volume vs its average

₹388.30NSE close · -0.10%

Delivery in the last 5 sessions: 43.9% · 37.1% · 43.6% · 41.4% · 45.7%

Date	Side	Counterparty	Value	Price	Quantity	Type
7 Oct	Sell	Oregano Life Private Limited	₹29.36 Cr	₹420.28	698,490	Bulk

Delivery across the market →All bulk and block deals →

A description of what the exchange published, not a recommendation. Names such as "accumulation" or "long buildup" label a pattern in the numbers. How delivery is analysed

📢 Recent Corporate Announcements

JSLL Submits Regulation 74(5) Demat Compliance Certificate for Q2 FY27

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 07 Oct 2026, 04:42 PM

Jeena Sikho Lifecare Limited has submitted its compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. The certificate covers the quarter and half-year ended September 30, 2026. It was issued by the company's Registrar and Share Transfer Agent, Skyline Financial Services Private Limited, on October 3, 2026. This is a standard quarterly regulatory submission confirming the processing of dematerialization requests.

Compliance certificate submitted for the quarter and half-year ended September 30, 2026
Certificate received from Registrar and Share Transfer Agent Skyline Financial Services Private Limited
RTA certificate dated October 3, 2026, submitted to exchanges on October 7, 2026

💡 No action required. Investors should track upcoming Q2 financial results and business operational updates.

Jeena Sikho Lifecare Launches 8 Ayurvedic and Nutraceutical Products in Domestic Market

🟢 POSITIVE ⭐ 5/10

EXPANSION 📅 05 Oct 2026, 06:12 PM

Jeena Sikho Lifecare Limited (JSLL) announced the launch of 8 new Ayurvedic healthcare, wellness, and nutraceutical products on October 5, 2026. The new offerings include two tablet formulations (Acharya Ji Arogyam and Nirogyam Vati), three pain management products under the 'Jod Xpert' range (oil, roll-on, tablet), and three plant protein powders targeting general, men, and women categories. All products are focused entirely on the domestic market, supporting the company's stated strategic push into the OTC wellness segment. Financial targets or expected revenue contributions from these specific launches were not disclosed in the filing.

Launched 8 new products across Ayurvedic healthcare, wellness, and nutraceutical segments on October 5, 2026
Product rollout includes 3 pain management variants under the 'Jod Xpert' brand (100 ml oil, 50 ml roll-on, 60 tablets)
Introduced 3 nutraceutical plant protein products (500 gm jars in chocolate, mango, and coffee flavours)
100% focused on the domestic Indian market across all 8 launches

💡 Track the upcoming quarterly revenue disclosures to see how fast these OTC products scale toward the company's broader OTC revenue target of ₹300-500 Cr.

Jeena Sikho Lifecare Receives NABH Accreditation for Raipur Hospital Through August 2029

🟢 POSITIVE ⭐ 3/10

REGULATORY 📅 01 Oct 2026, 06:29 PM

Jeena Sikho Lifecare Limited has been granted NABH accreditation for its hospital located at Raipur, Chhattisgarh, specifically for Panchakarma services. The accreditation certificate (AH-2026-0513) is valid through August 20, 2029. The company stated this development occurred in the ordinary course of business and does not involve capacity expansion or capital expenditure. With the company targeting an increase in overall bed occupancy from 57% toward 80%, quality accreditations support standardisation and credibility across its network.

NABH accreditation granted for Raipur hospital located in Chhattisgarh
Accreditation certificate number AH-2026-0513 is valid until August 20, 2029
Specific service accredited is Panchakarma
Company clarified the development does not constitute business expansion or capacity enhancement

💡 Track whether accredited facilities help drive higher private patient occupancy and improve average revenue per bed (INR 8,324 in Q2 FY26) in upcoming quarterly updates.

Promoter Bhavna Grover Acquires 25,000 Shares of Jeena Sikho Lifecare via Open Market

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 30 Sep 2026, 01:10 PM

Promoter and Whole Time Director Bhavna Grover purchased 25,000 equity shares of Jeena Sikho Lifecare Limited on September 29, 2026, through open-market transactions. This acquisition represents approximately 0.02% of the company's total equity capital, valued at roughly ₹1.25 crore based on recent market prices. Following the purchase, Grover's direct stake increased from 0.22% (2,78,000 shares) to 0.24% (3,03,000 shares). Total promoter and promoter group shareholding edged up marginally from 63.62% to 63.66%.

Acquisition of 25,000 equity shares (0.02% of total capital) via open market on September 29, 2026
Individual holding increased from 2,78,000 shares (0.22%) to 3,03,000 shares (0.24%)
Overall promoter group holding increased slightly from 63.62% to 63.66%
Total diluted share capital remains unchanged at 12,43,00,730 equity shares (₹24.86 crore)

💡 Track whether open-market purchases by promoters continue in subsequent filings, and monitor quarterly shareholding patterns alongside Q2 FY27 earnings.

Promoter Bhavna Grover Acquires 35,000 Shares (0.02%) via Open Market

🟢 POSITIVE ⭐ 3/10

ROUTINE 📅 29 Sep 2026, 01:19 PM

Promoter and Whole Time Director Bhavna Grover purchased 35,000 equity shares of Jeena Sikho Lifecare Limited through the open market on September 28, 2026. This transaction represents an acquisition of 0.02% of the company's total voting capital. Following this purchase, her individual shareholding increased from 2,43,000 shares (0.20%) to 2,78,000 shares (0.22%). Consequently, total aggregate promoter group holding increased slightly from 63.62% to 63.64%.

Purchase of 35,000 equity shares via open market on September 28, 2026
Acquirer's holding increased from 0.20% (2,43,000 shares) to 0.22% (2,78,000 shares)
Total promoter and promoter group shareholding edged up from 63.62% to 63.64%
Total diluted equity base stands unchanged at 12,43,00,730 equity shares of Rs 2 each

💡 Track whether insider buying continues across subsequent quarters as an indicator of promoter confidence amid the stock's recent price drawdown.

Jeena Sikho Lifecare Launches 2 New Ayurvedic Tablet Products in Domestic Market

🟡 NEUTRAL ⭐ 4/10

EXPANSION 📅 21 Sep 2026, 06:38 PM

Jeena Sikho Lifecare Limited (JSLL) announced the launch of two new Ayurvedic tablet products on September 21, 2026: Acharya Ji's Amrit Tattava Vati (60 Tablets) and Acharya Ji's Oja Amrit Vati (60 Tablets). Both formulations target the domestic market to expand the company's healthcare and wellness portfolio. While part of JSLL's broader stated strategy to scale its Over-The-Counter (OTC) segment toward Rs 300-500 Cr in revenue, no specific revenue estimates or pricing for these individual launches were disclosed. The immediate financial impact relative to JSLL's TTM revenue of Rs 852 Cr remains modest.

Launched 2 new Ayurvedic products on September 21, 2026
Products introduced: Acharya Ji's Amrit Tattava Vati and Acharya Ji's Oja Amrit Vati, both in 60 Tablets pack sizes
Both products cater exclusively to the domestic Indian market
Revenue and pricing potential for the new products was not disclosed

💡 Track subsequent quarterly filings to evaluate traction in the OTC Ayurvedic segment against management's stated target of reaching Rs 300-500 Cr in OTC product revenue.

JSLL Postpones Operations at 2,300 Sq. Ft. Ayodhya Day Care Clinic to Late September 2026

🟡 NEUTRAL ⭐ 3/10

EXPANSION 📅 09 Sep 2026, 02:38 PM

Jeena Sikho Lifecare Limited has announced a postponement in commencing commercial operations at its upcoming Day Care Clinic in Ayodhya, Uttar Pradesh. Originally intimated on June 11, 2026, the ~2,300 sq. ft. facility is now scheduled to begin operations toward the end of September 2026. The delay is attributed to final operational arrangements and site readiness. Given the minor footprint relative to the company's Rs 852 Cr TTM revenue base, the financial impact of this short delay is negligible.

Commercial operations at the Ayodhya Day Care Clinic deferred to end of September 2026
Clinic covers an estimated area of approximately 2,300 sq. ft.
Facility address located at 5/13/62 Khwashpura, Ram path road, Ayodhya (U.P.)
Originally intimated to the exchanges on 11th June, 2026

💡 Track confirmation of commissioning by the end of September 2026 and monitor overall progress on company's 7,000-10,000 bed expansion plans.

JSLL Postpones Ayodhya Day Care Clinic Launch to Late September 2026

🟡 NEUTRAL ⭐ 3/10

EXPANSION 📅 09 Sep 2026, 02:37 PM

Jeena Sikho Lifecare Limited (JSLL) has announced a postponement in commencing commercial operations at its new Day Care Clinic in Ayodhya, Uttar Pradesh. Originally intimated on June 11, 2026, the facility spanning approximately 2,300 sq. ft. is now expected to begin operations by the end of September 2026. The delay is attributed to the completion of operational arrangements and site readiness. Given JSLL's extensive footprint (over 2,800 operational beds across multiple states and Rs 852 Cr TTM revenue), a short delay for a single 2,300 sq. ft. day care clinic has immaterial financial impact.

Commercial operations at the Ayodhya Day Care Clinic postponed to late September 2026
Clinic covers an estimated area of approximately 2,300 sq. ft.
Facility address is 5/13/62 Khwashpura, Ram path road, Ayodhya, Uttar Pradesh
Postponement follows the original setup intimation dated June 11, 2026

💡 Track the formal operational launch confirmation by late September 2026, though the financial impact on overall operations remains minimal.

JSLL Receives NABH Accreditation for Pune Hospital Valid Till July 2029

🟢 POSITIVE ⭐ 3/10

REGULATORY 📅 08 Sep 2026, 04:28 PM

Jeena Sikho Lifecare Limited (JSLL) has been awarded NABH accreditation for its Pune Hospital covering Panchakarma services. The accreditation (Certificate No. AH-2026-0505) is valid until July 27, 2029. The company stated this development occurred in the ordinary course of business and does not involve capacity expansion or capital expenditure. NABH quality recognition typically helps hospitals qualify for insurance empanelment and improves patient trust.

Received NABH accreditation for Pune Hospital (Certificate No. AH-2026-0505)
Accreditation covers Panchakarma services at Bund Garden Road, Pune
Accreditation validity is through July 27, 2029
No change in bed capacity or capital outlay involved

💡 Monitor whether NABH accreditation leads to empanelment with third-party insurance administrators (TPAs) and increases higher-margin private patient footfalls in future quarters.

Jeena Sikho Lifecare Launches 2 New Ayurvedic Products in Domestic Market

🟡 NEUTRAL ⭐ 3/10

OTHER 📅 05 Sep 2026, 04:36 PM

Jeena Sikho Lifecare Limited (JSLL) has expanded its Ayurvedic healthcare and wellness portfolio by launching two new tablet formulations: 'Acharya Ji's Jeevanodya Vati' and 'Acharya Ji's Ojavardhan Vati'. Both products have been introduced in 60-tablet pack sizes catering to the domestic Indian market. This aligns with the company's stated strategic goal of expanding its Over-The-Counter (OTC) wellness portfolio alongside its existing hospital network. Financial projections or expected revenue contributions from these specific launches were not disclosed.

Launched 2 new Ayurvedic products: Acharya Ji's Jeevanodya Vati and Acharya Ji's Ojavardhan Vati
Both products launched in pack sizes of 60 Tablets
Effective launch date is 05th September 2026 for the domestic market
Part of ongoing portfolio expansion in the Ayurvedic wellness segment

💡 Track subsequent quarterly revenue traction in the OTC/wellness product segment to assess consumer uptake and distribution reach.

Jeena Sikho Lifecare Issues 9th AGM Notice; Proposes ₹4.50 Final Dividend for FY26

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 04 Sep 2026, 05:22 PM

Jeena Sikho Lifecare Limited has issued the notice for its 9th Annual General Meeting scheduled for September 28, 2026, alongside releasing its Integrated Annual Report for FY 2025-26. The company proposed a final dividend of ₹4.50 per equity share of face value ₹2. As of FY26, the company reported operational reach across 23 states with 2,861 total beds (2,300 operational) across 61 hospitals and 58 clinics, generating ₹801 Cr in revenue from operations. Shareholder approval is also sought for director appointments and loan/investment limits under Sections 185 and 186.

AGM scheduled for September 28, 2026, to approve FY26 financial statements and key resolutions
Proposed final dividend of ₹4.50 per equity share (face value ₹2) for FY26
Network footprint expanded to 2,861 total beds (2,300 operational) across 61 hospitals and 58 clinics
Annual revenue from operations reached ₹801 Cr across 119 operational centres and 100+ cities
Shareholder approval sought for inter-corporate loans and investments under Sections 185 and 186

💡 Track voting outcomes and shareholder approvals following the 9th AGM on September 28, 2026, and watch for record date notifications regarding the ₹4.50 dividend payout.

JSLL Issues FY26 Annual Report & AGM Notice; Recommends ₹4.50/Share Dividend

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 04 Sep 2026, 05:18 PM

Jeena Sikho Lifecare Limited has issued its Integrated Annual Report for FY25-26 and scheduled its 9th Annual General Meeting (AGM) for September 28, 2026. The Board has proposed a final dividend of ₹4.50 per equity share (face value ₹2 each). According to the annual report disclosures, the company operated 119 centres (61 hospitals and 58 clinics) with 2,861 total beds across 23 states, generating ₹801 Cr in revenue from operations for FY26. Key special resolutions include approvals for loans, guarantees, and securities under Sections 185 and 186 of the Companies Act.

9th Annual General Meeting scheduled for September 28, 2026.
Proposed final dividend of ₹4.50 per equity share (face value ₹2).
Footprint expanded to 119 operational centres and 2,861 total beds (2,300 operational) across 23 states.
AYUSH and wellness portfolio spans over 330+ SKUs across 100+ cities.

💡 Track voting outcomes at the AGM on September 28, 2026, and note the record date for the final dividend payout.

JSLL Convenes 9th AGM on Sep 28, 2026; Proposes ₹4.50/Share Dividend and Dispatches Annual Report

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 04 Sep 2026, 05:16 PM

Jeena Sikho Lifecare Limited (JSLL) has issued the notice for its 9th Annual General Meeting scheduled for September 28, 2026. Key agenda items include the declaration of a final dividend of ₹4.50 per equity share (face value ₹2 each) for FY26. The accompanying FY26 Annual Report highlights an operational network spanning 2,861 total beds (2,300 operational) across 61 hospitals and 119 operational centres in 23 states, generating ₹801 Cr in revenue. Shareholders will also vote on board re-appointments and enabling approvals under Sections 185 and 186 for loans and guarantees.

9th Annual General Meeting scheduled for September 28, 2026 at Zirakpur, Punjab
Final dividend of ₹4.50 per equity share of face value ₹2 proposed for approval
Annual Report outlines a network of 2,861 total beds across 119 centres and 23 states
Resolutions include statutory approvals for loans, guarantees, and investments under Sections 185 and 186

💡 Track the shareholder voting results following the AGM on September 28, 2026, and the record date announcement for the ₹4.50 per share dividend payout.

Jeena Sikho Lifecare Launches 6 New Ayurvedic Healthcare Products in Domestic Market

🟡 NEUTRAL ⭐ 4/10

EXPANSION 📅 02 Sep 2026, 06:29 PM

Jeena Sikho Lifecare Limited (JSLL) announced the launch of six new Ayurvedic healthcare products on September 2, 2026, aimed at the domestic market. The launches span two brand lines: Narie Xpert and Porush Xpert, each introduced in three formats (80g granules, 500 ml syrup, and 52-count tablets). This product rollout aligns with the company's broader strategy to scale its Ayurvedic wellness and OTC product offerings alongside its hospital network (TTM revenue: Rs 852 Cr).

Launched 6 new products across Narie Xpert and Porush Xpert product lines on 02/09/2026
Product forms include 80g Granules, 500 Ml Syrup, and 52 Tab packs for both brands
All 6 newly launched SKUs cater exclusively to the Domestic Market
Expands existing portfolio of Ayurvedic, healthcare, and wellness offerings

💡 Track the distribution ramp-up, retail penetration, and revenue contribution from the new OTC/Ayurvedic lines in upcoming quarterly disclosures.

JSLL Sets Sept 21 as Record Date for ₹4.50/Share Final Dividend, AGM on Sept 28

🟡 NEUTRAL ⭐ 4/10

DIVIDEND 📅 31 Aug 2026, 05:07 PM

Jeena Sikho Lifecare Limited has scheduled its 9th Annual General Meeting (AGM) for Monday, September 28, 2026. The Board has fixed Monday, September 21, 2026, as the Record Date to determine shareholder eligibility for the previously recommended final dividend of ₹4.50 per equity share (face value ₹2). The share transfer books and Register of Members will remain closed from September 22 to September 28, 2026.

Final dividend fixed at ₹4.50 per equity share (face value ₹2 each) for FY26
Record date for dividend entitlement and cut-off date for remote e-voting set for September 21, 2026
9th Annual General Meeting scheduled for September 28, 2026 at 12:00 Noon
Book closure period scheduled from September 22, 2026 to September 28, 2026

💡 Investors seeking dividend eligibility must hold shares before the record date of September 21, 2026, and track AGM approvals on September 28, 2026.

View All JSLL Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Total revenue grew 66% YoY to INR 190 Cr in Q2 FY26. The product segment grew approximately 78% YoY, while the services segment contributed 50% of the total revenue during the quarter.

Geographic Revenue Split

The company operates across 23 states and 100+ cities in India. Specific percentage contribution per region is not disclosed, but the footprint has expanded to 2,802 beds as of Q2 FY26.

Profitability Margins

Net Profit (PAT) margin stood at 31% in Q2 FY26, an improvement of 810 bps YoY. The company targets a sustainable long-term healthy profit margin of 20% to 25%.

EBITDA Margin

EBITDA margin reached 48% in Q2 FY26, marking a significant increase from 35% in Q2 FY25 and 45% in Q1 FY26. EBITDA grew 129% YoY to INR 92 Cr.

Capital Expenditure

Cash used in investing activities was INR 70.37 Cr in FY25, primarily for property, plant, and equipment (INR 92.34 Cr total PPE). Setup costs for new facilities are optimized at INR 3-4 lakh per bed.

Credit Rating & Borrowing

The company took a debt of INR 10 Cr from a director to meet working capital requirements in FY25. Total borrowings stood at INR 10.73 Cr (INR 0.43 Cr non-current and INR 10.30 Cr current) as of FY25.

⚙️ Operational Drivers

Raw Materials

Ayurveda medicines (exclusively supplied by JSLL to franchises) and Panchakarma equipment. Specific cost percentages for individual raw materials are not disclosed.

Import Sources

Sourced within India to support the 117 facilities across 23 states.

Key Suppliers

JSLL acts as the exclusive supplier of Ayurveda medicines to its 35 franchise-operated clinics and day-care centers.

Capacity Expansion

Current operational capacity is 2,220 beds as of Q2 FY26, with a total of 2,802 beds reached within the first half of the year. Planned expansion targets 7,000 to 10,000 beds within the next 3 to 5 years.

Raw Material Costs

Inventory stood at INR 2.95 Cr in FY25, down from INR 3.50 Cr in FY24. The company uses a capital-light model where medicines are bundled with services.

Manufacturing Efficiency

Bed occupancy was 57% in Q2 FY26. The company aims to increase utilization to 70-80% within the next 6 to 8 months to drive operating leverage.

Logistics & Distribution

The company is actively increasing its distributor chain to support the planned INR 300-500 Cr turnover from OTC and product marketing.

📈 Strategic Growth

Expected Growth Rate

66%

Growth Strategy

Growth will be driven by expanding bed capacity to 10,000 beds, increasing occupancy from 57% to 80%, and launching an OTC product segment targeting INR 300-500 Cr in revenue. The shift from Government Panel to higher-margin private business is also a key driver.

Products & Services

Ayurveda medicines, IPD (In-Patient Department) hospital services, OPD (Out-Patient Department) consultations, Day Care services, and Video-Call consultations.

Brand Portfolio

Jeena Sikho Lifecare Limited (JSLL).

New Products/Services

Introduction of diagnostics and wellness centers, alongside a major push into the OTC (Over-The-Counter) product market.

Market Expansion

Expansion into 23 states and 100+ cities, with recent analyst meets in Singapore (Dec 2025) to attract international institutional investors.

Strategic Alliances

Franchise model for 35 clinics/day-care centers where JSLL provides doctors and medicines while franchisees manage operations.

🌍 External Factors

Industry Trends

Growing trust and preference for alternative healthcare (Ayurveda) in India, evidenced by a 57% YoY increase in IPD and 67% YoY increase in OPD volumes.

Competitive Landscape

JSLL competes in the healthcare and Ayurveda sector, positioning itself through integrated services (clinics to hospitals) and product sales.

Competitive Moat

Capital-light hub-and-spoke model with low setup costs (INR 3-4 lakh per bed) and a 3-year average ROCE of 71%, providing a significant competitive advantage in scaling.

Macro Economic Sensitivity

Performance is subject to changes in the Indian macroeconomic environment and regulatory landscape for alternative healthcare.

Consumer Behavior

Increasing patient preference for bundled services (products + treatment) and digital health (121% YoY growth in video consultations).

⚖️ Regulatory & Governance

Industry Regulations

Compliance with Ind-AS accounting standards following migration to the Main Board in 2025. Appointment of M/s. Ankur Singh & Associates as Secretarial Auditor for FY26-FY30.

⚠️ Risk Analysis

Key Uncertainties

Material differences in actual results may arise from unforeseen changes in the regulatory landscape or macroeconomic environment. Government debtor delays pose a working capital risk.